Evidence map›Paper›PMID 31578305›Full record

ArticleJCI insight2019

Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality.

Asim Saha, Patricia A Taylor, Christopher J Lees, Angela Panoskaltsis-Mortari, Mark J Osborn, Colby J Feser, Govindarajan Thangavelu, Wolfgang Melchinger, Yosef Refaeli, Geoffrey R Hill and 12 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 12 institutions in 3 countries.

Asim SahaMasonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Patricia A TaylorMasonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Christopher J LeesMasonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Angela Panoskaltsis-MortariMasonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Mark J OsbornMasonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Colby J FeserMasonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Govindarajan ThangaveluMasonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Wolfgang MelchingerDepartment of Hematology, Oncology, and Stem-Cell Transplantation, Freiburg University Medical Center, Albert Ludwigs University Freiburg, Freiburg, Germany.
Yosef RefaeliDepartment of Dermatology, University of Colorado, Aurora, Colorado, USA.
Geoffrey R HillFred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, USA.
David H MunnDepartment of Pediatrics, Georgia Health Sciences University, Augusta, Georgia, USA.
William J MurphyDepartment of Dermatology, UC Davis School of Medicine, Sacramento, California, USA.
Jonathan S SerodyDepartment of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Ivan MaillardDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Katharina KreymborgDepartment of Immunology and Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Marcel van den BrinkDepartment of Immunology and Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Chen DongInstitute for Immunology and School of Medicine, Tsinghua University, Beijing, China.
Shuyu HuangDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Xingxing ZangDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
James P AllisonDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Robert ZeiserDepartment of Hematology, Oncology, and Stem-Cell Transplantation, Freiburg University Medical Center, Albert Ludwigs University Freiburg, Freiburg, Germany.
Bruce R BlazarMasonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
University of Minnesota Medical Center · USAlbert Einstein College of Medicine · USMemorial Sloan Kettering Cancer Center · USUniversity of Freiburg · DEAugusta University Health · USThe University of Texas MD Anderson Cancer Center · USTsinghua University · CNUniversity of California, Davis · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Michigan · USUniversity of North Carolina at Chapel Hill · USUniversity of Washington · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
Obesity and Energy Metabolism CoreP30DK050456 · NIDDK · UNIVERSITY OF MINNESOTA TWIN CITIES · PI CROW, SCOTT J · 1995 to 2015
$17.0M
Enhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7M
Notch Signaling in AlloimmunityR01AI091627 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI PEAR, WARREN S · 2011 to 2025
$6.0M
Reprogramming the TME for immunogenic antigen-presentationR01CA103320 · NCI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI MUNN, DAVID H. · 2003 to 2024
$6.0M
T-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
T CELL TARGETING FOR GVHDR37HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R. · 1998 to 2007
$3.2M
PTEN, Tregs and MDSCs in the tumor microenvironmentR01CA211229 · NCI · AUGUSTA UNIVERSITY · PI MUNN, DAVID H. · 2017 to 2021
$1.7M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA077598NCI NIH HHS R01 CA103320NCI NIH HHS R01 CA211229NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL118979NHLBI NIH HHS R37 HL056067NIAID NIH HHS R01 AI091627NIAID NIH HHS R37 AI034495NIDDK NIH HHS P30 DK050456
6 · The paper itself

Abstract

B7-H4 is a negative regulatory B7 family member. We investigated the role of host and donor B7-H4 in regulating acute graft-versus-host disease (GVHD). Allogeneic donor T cells infused into B7-H4-/- versus WT recipients markedly accelerated GVHD-induced lethality. Chimera studies pointed toward B7-H4 expression on host hematopoietic cells as more critical than parenchymal cells in controlling GVHD. Rapid mortality in B7-H4-/- recipients was associated with increased donor T cell expansion, gut T cell homing and loss of intestinal epithelial integrity, increased T effector function (proliferation, proinflammatory cytokines, cytolytic molecules), and reduced apoptosis. Higher metabolic demands of rapidly proliferating donor T cells in B7-H4-/- versus WT recipients required multiple metabolic pathways, increased extracellular acidification rates (ECARs) and oxygen consumption rates (OCRs), and increased expression of fuel substrate transporters. During GVHD, B7-H4 expression was upregulated on allogeneic WT donor T cells. B7-H4-/- donor T cells given to WT recipients increased GVHD mortality and had function and biological properties similar to WT T cells from allogeneic B7-H4-/- recipients. Graft-versus-leukemia responses were intact regardless as to whether B7-H4-/- mice were used as hosts or donors. Taken together, these data provide new insights into the negative regulatory processes that control GVHD and provide support for developing therapeutic strategies directed toward the B7-H4 pathway.

Indexed as

Tissue DonorsAnimalsBone Marrow TransplantationCell Line, TumorCell ProliferationCytokinesDisease Models, AnimalFemaleGastrointestinal TractGraft vs Host DiseaseLungLymphomaMetabolic Networks and PathwaysMiceMice, Inbred BALB CMice, Inbred C57BLCytokinesV-Set Domain-Containing T-Cell Activation Inhibitor 1Vtcn1 protein, mouseBone marrow transplantationImmunologyT cellsTransplantation

Identifiers

PMID31578305
PMCPMC6795410
OpenAlexW2978186237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.